Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medmix AGMDMXF 68 Debt-to-Equity is 0.75 as of Jun. 2026, which is 1% below its 10-year median of 0.76. GuruFocus rates MDMXF with a GF Score™ of 68/100 and a GF Value™ of $17.95. The stock has 6 warning signs investors should review. Among 2,679 Industrial Products companies, Medmix AG ranks worse than 79.28% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medmix AG's Debt-to-Equity or its related term are showing as below:
MDMXF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.6 Med: 0.76 Max: 2.08
Current: 0.75
During the past 8 years, the highest Debt-to-Equity Ratio of Medmix AG was 2.08. The lowest was 0.60. And the median was 0.76.
MDMXF's Debt-to-Equity is ranked worse than 79.28% of 2679
companies
in the Industrial Products industry
Industry Median: 0.28
vs MDMXF: 0.75
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medmix AG Debt-to-Equity Related Terms
Medmix AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Medmix AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Medmix AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG Debt-to-Equity vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medmix AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medmix AG (MDMXF) has a Debt-to-Equity of 0.75 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medmix AG and its competitors. This is near median its historical median of 0.76. Over the past decade, Medmix AG's Debt-to-Equity has ranged from 0.60 to 2.08. According to the industry distribution chart, Medmix AG ranks #2124 out of 2679 companies in the Industrial Products industry, placing it in the top 79.3%.
Is Medmix AG's Debt-to-Equity too high?
Medmix AG's current Debt-to-Equity of 0.75 is near median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 2.08. The Industrial Products industry median Debt-to-Equity is 0.28. Medmix AG's value of 0.75 is 167.9% above this industry median. Based on the distribution chart, Medmix AG ranks #2124 out of 2679 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Medmix AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Debt-to-Equity compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #2124 out of 2679 companies for Debt-to-Equity. This places Medmix AG in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Medmix AG's value of 0.75 is 167.9% above this benchmark. Historically, Medmix AG's own Debt-to-Equity has ranged from 0.60 to 2.08 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.28, Medmix AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for an Industrial Products company?
The median Debt-to-Equity among Industrial Products companies is 0.28, based on 2,679 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current Debt-to-Equity of 0.75 is 167.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current Debt-to-Equity is 0.75, which is near median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current Debt-to-Equity of 0.75. The stock's GF Value™ is $17.95, compared to a current price of $17.40 — trading 3.1% below its estimated fair value. The current Debt-to-Equity is 0.75, which is near median its 10-year median of 0.76 and 167.9% above the Industrial Products industry median of 0.28. Medmix AG's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medmix AG (MDMXF), the current Debt-to-Equity is 0.75 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of $17.40 is trading 3.1% below its estimated GF Value™ of $17.95.
Key valuation signals for MDMXF:
Debt-to-Equity: 0.75 (near median its 10-year median of 0.76)
GF Value™: $17.95 vs. price of $17.40 (3.1% below fair value)
Industry Position: 167.9% above the Industrial Products median (#2124 of 2679)
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
68GF Score
Get the complete analysis for MDMXF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
